CPI-613 is a drug developed by Rafael to target the altered regulation of metabolic processes of cancer cells. Credit: Photo by rawpixel on Unsplash.

Rafael Pharmaceuticals has commenced a Phase II trial to investigate the efficacy and safety of CPI-613 in combination with modified folfirinox (mFFX) for the treatment of patients with localised borderline and unresectable pancreatic cancer.

CPI-613 is a drug developed by Rafael to target the altered regulation of metabolic processes of cancer cells, while mFFX is a standard combination of drugs.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Rafael plans to enrol 33 subjects with Eastern Cooperative Oncology Group (ECOG) performance status 0-1 as part of the open-label, single-armed trial.

Patients will receive the study drug combination over a period of six months and will be followed until death or three years from the date of completion of the trial.

“We hope to identify a strategy to extend the lives of patients with pancreatic cancer, and increase the patient eligibility for surgery.”

The trial’s primary endpoint is to identify the potential increase in overall survival (OS) and to further evaluate the safety of the CPI-613+ mFFX combination.

Its secondary endpoints comprise progression-free survival (PFS), time to progression (TTP), resection margins and others.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Phase II trial will be conducted in collaboration with University Hospitals Cleveland Medical Center in the US.

The trial’s lead investigator Jeffery Hardacre said: “Through this trial, we hope to identify a strategy to extend the lives of patients with pancreatic cancer, and increase the patient eligibility for surgery for those with locally advanced disease.”

Rafael previously assessed the safety, tolerability, and efficacy of the CPI-613 and mFFX combination in patients with first-line metastatic pancreatic cancer.

The study included a single-centre, open-label, dose-escalation design and included 20 patients.